LUMITIN
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

LUMITIN Trademark

Serial Number: 79149533 • Registration: 4741346

LUMITIN is a trademark filed by Chengdu Kanghong Pharmaceuticals GroupCo., Ltd. on March 28, 2014. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Chengdu Kanghong Pharmaceuticals GroupCo., Ltd.

No.36, Shuxi Rd.

Entity Type: 99

Trademark Details

Filing Date

March 28, 2014

Registration Date

May 26, 2015

Published for Opposition

March 10, 2015

Cancellation Date

March 29, 2024

Goods & Services

Medicines for humans used for the treatment of choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-relatedmacular degeneration, retinal vein occlusion, neoplastic disease and cancer, angiogenesis disease; Pharmaceutical preparations for the treatment of diabetes, cardiovascular disease and disorder, neoplastic disease and disorder, cancer, disease and disorder of immune system, angiogenesis disease and disorder, ophthalmic diseases and disorder, mental disease and disorder, aged-related macular degeneration; Injectable preparations for medical use, namely, for the treatment of oculopathy, choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-related macular degeneration, retinal vein occlusion, neoplastic disease, angiogenesis disease and cancer; Aqueous formula, namely, water-based pharmaceutical preparations for the treatment of cardiovascular disease and disorder, neoplastic disease and disorder, disease and disorder of immune system, ophthalmic diseases and disorder, inflammation; Biochemical drugs and preparations for medical use, namely, for the prevention, treatment and alleviation of angiogenesis disease, oculopathy, neoplastic disease, cancer, all of the foregoing being available by prescription only

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Oct 18, 2024 DENA
DEATH OF INTERNATIONAL REGISTRATION
Oct 18, 2024 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Oct 31, 2022 INNT
GENERIC MADRID TRANSACTION SENT TO IB
Sep 22, 2022 XXSS
GENERIC MADRID TRANSACTION CREATED
Sep 22, 2022 XXCR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 10, 2022 INTR
CANCELLED SECTION 71
Dec 10, 2021 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Jun 5, 2021 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
May 26, 2020 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 9, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 23, 2015 FICS
FINAL DISPOSITION PROCESSED
Sep 23, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 26, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
May 26, 2015 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2015 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2015 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 18, 2015 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 31, 2015 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 29, 2015 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 8, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 8, 2015 CRFA
ASSIGNED TO LIE
Jan 8, 2015 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 6, 2015 TROA
REFUSAL PROCESSED BY IB
Aug 22, 2014 RFNT
APPLICATION FILING RECEIPT MAILED
Aug 2, 2014 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 1, 2014 RFCS
REFUSAL PROCESSED BY MPU
Aug 1, 2014 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 1, 2014 RFCR
NON-FINAL ACTION WRITTEN
Jul 31, 2014 CNRT
ASSIGNED TO EXAMINER
Jul 29, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 29, 2014 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 24, 2014 REPR